Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Clin Cancer Res. 2014 Aug 12;20(19):5085–5096. doi: 10.1158/1078-0432.CCR-14-1038

Figure 5. Inhibition of HRR and Rad51 focus formation by AZD1775.

Figure 5

(A, B) MiaPaCa-2 cells stably expressing the DR-GFP homologous recombination repair reporter were infected with I-SceI-expressing adenovirus and treated for 24 hours with increasing concentrations of AZD1775 (A) or 200nM AZD1775 and 1μM olaparib (B) and assayed for GFP positivity by flow cytometry. Data are the mean percentage ± SE of n=3–4 independent experiments performed in duplicate. Statistical significance (P<0.05) is indicated vs control*. C and D, MiaPaCa-2 cells were treated with AZD1775 (200nM) and olaparib (1μM) for 1 hour pre- and 24 hours post-RT (6Gy). At the end of treatment, cells were stained for Rad51 (red) and with DAPI (blue). Images are from a single representative experiment (C). Data are the mean percentage ± SE of Rad51 positive cells (cells containing 5 or more Rad51 foci) from n=3 independent experiments. Statistical significance (P<0.05) is indicated vs RT* and olaparib+RT¥.